Short answer
MYRIAD GENETICS INC (MYGN) filed an 8-K current report with the SEC on October 9, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Former Chief Commercial Officer Brian Donnelly’s separation became effective September 21, 2026.
MYRIAD GENETICS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Former Chief Commercial Officer Brian Donnelly’s separation became effective September 21, 2026
- $1,322,294 lump-sum severance payment, subject to release and restrictive covenants
- Time-based equity awards vesting within two years accelerated, increasing near-term compensation expense
- Performance-based awards remain contingent on achievement through two years after separation
- Agreement effective October 14, 2026, unless Donnelly revokes it
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other MYRIAD GENETICS INC 8-K filings
Get the next MYGN 8-K as it lands
Follow MYGN for push alerts, or ask the research agent what this filing means.